Dyloject diclofenac sodium: Phase I data

Data from an open-label Phase I trial evaluating a 37.5 mg IV bolus of Dyloject in 13 patients with renal impairment showed that 8 patients with hepatic impairment and 19 healthy volunteers showed no ...